Close Menu

Perlegen

Movers & Shakers: Apr 22, 2011

Premium

Gregory Critchfield, Mark Ostrowski, Dennis Farrar

PGx Reporter's most-read stories in 2010 delved into the complex scientific challenges, business strategies, and legislative issues impacting the field of pharmacogenomics.

The Australian firm has acquired, among other assets, the BrevaGen breast cancer risk test, which it expects to launch in the second half of this year.

A review of the privately held pharmacogenomics company's activities from when it opened its doors in 2000 to just before it shuttered in late 2009 suggests that despite partnerships with academia and big pharma, opportunistic R&D investments in key markets, and at least one recently launched commercial diagnostic product, the company was unable to remain solvent. R&D disappointments, losses related to a government contract, and the economic crisis may have directly forced the company to close.

The demise of Perlegen Sciences and Decision Biomarkers adds two more names to a growing list of array-related firms and businesses that have gone belly up or have been shuttered in the past few years.

The firm shuttered its operations at the end of October.

The genetic testing company plans to use the lab to offer a breast cancer risk test beginning in the fall.

Mark Schmeizl, David Sneider, David Cox, Joshua LaBaer

Elias Zerhouni has joined the Gates Foundation, Aushon Biosystems has named a new VP of North American Sales, Joshua LaBaer heads West to Arizona State University, and more.

Pages

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.